Cargando…

Combined PI3Kα-mTOR Targeting of Glioma Stem Cells

Glioblastoma (GBM) is the most common and lethal primary intrinsic tumour of the adult brain and evidence indicates disease progression is driven by glioma stem cells (GSCs). Extensive advances in the molecular characterization of GBM allowed classification into proneural, mesenchymal and classical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eckerdt, Frank D., Bell, Jonathan B., Gonzalez, Christopher, Oh, Michael S., Perez, Ricardo E., Mazewski, Candice, Fischietti, Mariafausta, Goldman, Stewart, Nakano, Ichiro, Platanias, Leonidas C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736588/ https://www.ncbi.nlm.nih.gov/pubmed/33318517 http://dx.doi.org/10.1038/s41598-020-78788-z

Ejemplares similares

Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
por: Eckerdt, Frank, et al.
Publicado: (2019)

Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition
por: Iqbal, Asneha, et al.
Publicado: (2016)

SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression
por: Fischietti, Mariafausta, et al.
Publicado: (2022)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance
por: Eckerdt, Frank, et al.
Publicado: (2023)

Human SLFN5 is a Transcriptional Co-repressor of STAT1-Mediated Interferon Responses and Promotes the Malignant Phenotype in Glioblastoma
por: Arslan, Ahmet Dirim, et al.
Publicado: (2017)

MNK Proteins as Therapeutic Targets in Leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

A novel approach to overcome drug resistance in acute myeloid leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways
por: Mazewski, Candice, et al.
Publicado: (2020)

Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
por: Colardo, Mayra, et al.
Publicado: (2021)

Targeting mTOR for the treatment of AML. New agents and new directions
por: Altman, Jessica K., et al.
Publicado: (2011)

HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma
por: Bell, Jonathan B., et al.
Publicado: (2018)

Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells
por: Saleiro, Diana, et al.
Publicado: (2023)

Inhibitory effects of SEL201 in acute myeloid leukemia
por: Kosciuczuk, Ewa M., et al.
Publicado: (2019)

Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells
por: Eckerdt, Frank, et al.
Publicado: (2014)

Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
por: Colamonici, Marco, et al.
Publicado: (2015)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway
por: Jin, Qianxu, et al.
Publicado: (2022)

Peptide ARHGEF9 Inhibits Glioma Progression via PI3K/AKT/mTOR Pathway
por: Huang, Jie, et al.
Publicado: (2023)

Retracted: Peptide ARHGEF9 Inhibits Glioma Progression via PI3K/AKT/mTOR Pathway
por: Markers, Disease
Publicado: (2023)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
por: McBride, Sean M., et al.
Publicado: (2009)

Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway
por: Zhao, Kai-Hong, et al.
Publicado: (2017)

Celastrol Suppresses Glioma Vasculogenic Mimicry Formation and Angiogenesis by Blocking the PI3K/Akt/mTOR Signaling Pathway
por: Zhu, Yingjun, et al.
Publicado: (2020)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
por: Pyuen, Alex A., et al.
Publicado: (2018)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme
por: Yao, Weiqi, et al.
Publicado: (2021)

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
por: Moore, Gillian, et al.
Publicado: (2021)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nvfuuslrggr8o335cabssm4eeu